Showing 721-730 of 1942 results for "".
Special Report: Update on Holland Foundation
https://modernod.com/podcasts/eyewire-news-the-podcast/special-report-update-on-holland-foundation/37090/The leaders of the Holland Foundation provide an update on the progress of the foundation and its mission to restore sight for patients with Severe Ocular Surface Disease. Learn more about your ad choices. Visit megaphone.fm/adchoicesFirst Myopia Drug Approved in Europe
https://modernod.com/podcasts/eyewire-news-the-podcast/first-myopia-drug-approved-in-europe/37088/The first pharmaceutical treatment for myopia is approved in Europe; the FDA sets a target action date for a first-of-its-kind presbyopia drop; and John Berdahl, MD, discusses the reimbursement landscape in ophthalmology. Learn more about your ad choices. Visit megaphone.fm/adchoicesOphthalmic Leaders Launch SightLine Meeting
https://modernod.com/podcasts/eyewire-news-the-podcast/ophthalmic-leaders-launch-sightline-meeting/37083/Commercial stakeholders discuss the challenges and opportunities in ophthalmology in this special edition of Eyewire News: The Podcast. Learn more about your ad choices. Visit megaphone.fm/adchoicesFDA Issues CRL to Regeneron for Eylea HD Extended Dosing
https://modernod.com/podcasts/eyewire-news-the-podcast/fda-issues-crl-to-regeneron-for-eylea-hd-extended-dosing/37081/The FDA responds to Regeneron’s request to extend dosing intervals for Eylea HD; Regeneron applies for a new indication for Eylea HD; and several recent executive appointments are announced in the ophthalmology industry. Learn more about your ad choices. Visit megaphone.fm/adchoicesOrasis Launches Presbyopia Eye Drop Qlosi
https://modernod.com/podcasts/eyewire-news-the-podcast/orasis-launches-presbyopia-eye-drop-qlosi/37080/A presbyopia drop is officially launched in the US; Nordic Pharma receives European approval for its novel dry eye therapy; and Tenpoint submits an NDA for a presbyopia eye drop candidate. Learn more about your ad choices. Visit megaphone.fm/adchoicesFDA Expands Product Label for Iluvien
https://modernod.com/podcasts/eyewire-news-the-podcast/fda-expands-product-label-for-iluvien/37076/Iluvien receives a major label expansion; Bausch and Lomb launches a new orthokeratology lens fitting system; and several updates are announced in development wet AMD candidates. Learn more about your ad choices. Visit megaphone.fm/adchoicesNew Myopia Software on Pentacam AXL
https://modernod.com/podcasts/eyewire-news-the-podcast/new-myopia-software-on-pentacam-axl/37073/Oculus launches new myopia software on its Pentacam AXL; the first clinical polygenic risk score test for glaucoma in the US is launched; and Virtual Vision Health releases visual acuity testing on its VR platform Learn more about your ad choices. Visit megaphone.fm/adchoicesFDA Approves Genentech's Susvimo Ocular Implant for DME
https://modernod.com/podcasts/eyewire-news-the-podcast/fda-approves-genentechs-susvimo-ocular-implant-for-dme/37070/The FDA approves a label expansion for Genentech’s Susvimo implant; Iantrek completes the first commercial cases of its C.Rex micro-interventional system; and there are several executive leadership announcements made in ophthalmology. Learn more about your ad choices. Visit megaphone.fm/adchoicesPhase 3 Results for Novel Sedation Tablet
https://modernod.com/podcasts/eyewire-news-the-podcast/phase-3-results-for-novel-sedation-tablet/37062/New phase 3 data is released for a non-opioid sedation tablet; the first patient is dosed in the phase 3 trial of EyePoint’s wet AMD candidate; and Outlook receives a reimbursement decision in the UK for its wet AMD treatment. Learn more about your ad choices. Visit megaphone.fm/adchoicesPhakic IOL for Presbyopia Approved in Europe
https://modernod.com/podcasts/eyewire-news-the-podcast/phakic-iol-for-presbyopia-approved-in-europe/37061/A new phakic IOL for presbyopia is approved in Europe; Nidek launches its preloaded Toric IOL Injection System internationally; and the FDA cleared a novel device for the treatment of Meibomian Gland Dysfunction. Learn more about your ad choices. Visit megaphone.fm/adchoices